companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2022
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 7,416,455 and a net result of DKK 466,886 compared with DKK -631,427 the year before. That is an increase of 62.5% compared with the year before. Equity amounted to DKK 2,746,235. The solvency ratio was 10.7%. The company had 12 employees in the financial year.
- Gross Profit
- 7,416,455 kr.
- Profit/Loss
- 466,886 kr.
- Equity
- 2,746,235 kr.
- Total Assets
- 25,639,890 kr.
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 7.4 mio. | 467 t. | 2.7 mio. | 12 |
| 2021 | - | 4.6 mio. | -631 t. | 2.3 mio. | 10 |
| 2020 | - | 4.5 mio. | -238 t. | 2.9 mio. | 10 |
| 2019 | - | 5.8 mio. | 1.3 mio. | 3.1 mio. | 10 |
Keep an eye on Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2021. Gross profit came to DKK 4,563,506, and the net result was DKK -631,427.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.